Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody

被引:23
作者
Zhang, ML
Sakahara, H
Yao, ZS
Saga, T
Nakamoto, Y
Sato, N
Nakada, H
Yamashina, I
Konishi, JJ
机构
[1] KYOTO UNIV,FAC MED,DEPT NUCL MED,SAKYO KU,KYOTO 60601,JAPAN
[2] KYOTO SANGYO UNIV,FAC ENGN,DEPT BIOTECHNOL,KYOTO,JAPAN
来源
NUCLEAR MEDICINE AND BIOLOGY | 1997年 / 24卷 / 01期
关键词
biotinylated antibody; radiolabeled streptavidin; avidin chase; intraperitoneal xenografts;
D O I
10.1016/S0969-8051(96)00162-X
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In the present study, we examined the effect of avidin administered intravenously (i.v.) on the biodistribution of radiolabeled streptavidin in mice bearing intraperitoneal (IF) xenografts pretargeted with biotinylated antibody. Tumors were established in nude mice by IP inoculation of LS180 human colon cancer cells. Monoclonal antibody MLS128, which recognizes Tn antigen on mucin, was biotinylated and injected IP into the IP tumor-bearing mice. Radioiodinated streptavidin was administered IP or i.v. 48 h after pretargeting of biotinylated antibody. Avidin was administered i.v. 30 min prior to streptavidin injection. The localization of radioiodinated streptavidin in the tumor pretargeted with biotinylated antibody was significantly higher than that without pretargeting and that of radioiodinated MLS128 by the one-step method. Avidin administration significantly accelerated the clearance of radioiodinated streptavidin in blood and other normal tissues and increased the tumor-to-blood radioactivity ratio regardless of administration route of streptavidin. The i.v. avidin chase improved tumor localization of radiolabeled streptavidin in the IP xenografts pretargeted with biotinylated antibody. Copyright (C) 1997 Elsevier Science Inc.
引用
收藏
页码:61 / 64
页数:4
相关论文
共 20 条
[1]   STREPTAVIDIN CONTAINS AN RYD SEQUENCE WHICH MIMICS THE RGD RECEPTOR DOMAIN OF FIBRONECTIN [J].
ALON, R ;
BAYER, EA ;
WILCHEK, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 170 (03) :1236-1241
[2]  
CHATAL JF, 1989, CANCER RES, V49, P3087
[3]   SINGLE-DOSE INTRAPERITONEAL RADIOIMMUNOTHERAPY WITH THE MURINE MONOCLONAL-ANTIBODY I-131 MOV18 - CLINICAL-RESULTS IN PATIENTS WITH MINIMAL RESIDUAL DISEASE OF OVARIAN-CANCER [J].
CRIPPA, F ;
BOLIS, G ;
SEREGNI, E ;
GAVONI, N ;
SCARFONE, G ;
FERRARIS, C ;
BURAGGI, GL ;
BOMBARDIERI, E .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (05) :686-690
[4]  
ESTEBAN JM, 1990, CANCER RES, V50, pS989
[5]  
GOODWIN DA, 1995, J NUCL MED, V36, P876
[6]  
Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8
[7]  
HNATOWICH DJ, 1987, J NUCL MED, V28, P1294
[8]  
KHAWLI LA, 1993, ANTIBODY IMMUNOCONJ, V6, P13
[9]  
KOBAYASHI H, 1994, J NUCL MED, V35, P1677
[10]   INTRAPERITONEAL RADIOIMMUNOTHERAPY OF REFRACTORY OVARIAN-CARCINOMA UTILIZING IODINE-131-LABELED MONOCLONAL-ANTIBODY OC125 [J].
MUTO, MG ;
FINKLER, NJ ;
KASSIS, AI ;
HOWES, AE ;
ANDERSON, LL ;
LAU, CC ;
ZURAWSKI, VR ;
WEADOCK, K ;
TUMEH, SS ;
LAVIN, P ;
KNAPP, RC .
GYNECOLOGIC ONCOLOGY, 1992, 45 (03) :265-272